Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry.

Raymond K CrossApril N NaegeliRyan W HarrisonPage C MooreRachel H MackeyMargaux M CrabtreeCeleste A LemayVipin AroraNathan MorrisAngelina SontagCem KayhanJoshua R Korzenik

Published in: Crohn's & colitis 360 (2022)

Among UC patients in a real-world setting, BIO/JAKi patients had less remission, more moderate-to-severe disease, and worse PROs than 5-ASAs patients. These results suggest that despite increased therapeutic options, patients with UC currently being treated with biologics or JAKi may still experience disease burden and continued unmet needs.

Keyphrases

end stage renal disease
patient reported outcomes
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
ulcerative colitis
healthcare
risk factors
early onset